特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インフルエンザワクチンの世界市場:ワクチンタイプ、種類、技術、年齢層、投与経路別 - 市場機会の分析と産業予測 2019年~2026年

Influenza Vaccine Market by Vaccine Type, Type, Technology, Age Group, and Route of Administration : Global Opportunity Analysis and Industry Forecast, 2019-2026

発行 Allied Market Research 商品コード 917215
出版日 ページ情報 英文 226 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
インフルエンザワクチンの世界市場:ワクチンタイプ、種類、技術、年齢層、投与経路別 - 市場機会の分析と産業予測 2019年~2026年 Influenza Vaccine Market by Vaccine Type, Type, Technology, Age Group, and Route of Administration : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日: 2019年10月01日 ページ情報: 英文 226 Pages
概要

世界のインフルエンザワクチン市場は、2018年に39億6,000万米ドルと評価され、2019年から2026年にかけては5.9%のCAGRで推移し、2026年までに62億ドル規模の市場に成長すると予測されています。

当レポートでは、世界のインフルエンザワクチン市場を調査し、市場の概要、ワクチンタイプ・インフルエンザタイプ・技術・年齢層・投与経路・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • レポート概要
  • ステークホルダーの主な利点
  • 主要市場セグメント
  • 調査方法

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • ファイブフォース分析
  • 市場シェア分析
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会

第4章 世界のインフルエンザワクチン市場:ワクチンタイプ別

  • 市場概況
  • 四価ワクチン
    • 市場動向・成長因子・市場機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 三価ワクチン

第5章 世界のインフルエンザワクチン市場:インフルエンザタイプ別

  • 市場概況
  • 季節性インフルエンザ用ワクチン
    • 市場動向・成長因子・市場機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 新型インフルエンザ用ワクチン

第6章 世界のインフルエンザワクチン市場:技術別

  • 市場概要
  • 卵由来
    • 市場動向・成長因子・市場機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 培養細胞由来

第7章 世界のインフルエンザワクチン市場:年齢層別

  • 市場概況
  • 小児
    • 市場動向・成長因子・市場機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 成人

第8章 世界のインフルエンザワクチン市場:投与経路別

  • 市場概況
  • 注射
    • 市場動向・成長因子・市場機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 経鼻スプレー

第9章 世界のインフルエンザワクチン市場:地域別

  • 市場概況
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第10章 企業プロファイル

  • Astrazeneca Plc
  • Biodiem
  • Csl Limited (Seqirus Gmbh)
  • Emergent Biosolutions
  • F. Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • Glaxosmithkline Plc
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.
図表

List of Tables

  • Table 01. Global Influenza Vaccine Market, By Vaccine Type, 2018-2026, ($Million)
  • Table 02. Influenza Vaccine Market For Quadrivalent, By Region, 2018-2026, ($Million)
  • Table 03. Influenza Vaccine Market For Trivalent, By Region, 2018-2026, ($Million)
  • Table 04. Global Influenza Vaccine Market, By Technology, 2018-2026 ($Million)
  • Table 05. Egg-Based Influenza Vaccine Market, By Region, 2018-2026 ($Million)
  • Table 06. Cell Culture Influenza Vaccine Market, By Region, 2018-2026 ($Million)
  • Table 07. Global Influenza Vaccine Market, By Age Group, 2018-2026, ($Million)
  • Table 08. Influenza Vaccine Market For Pediatric Age Group, By Region, 2018-2026, ($Million)
  • Table 09. Influenza Vaccine Market For Adult Age Group, By Region, 2018-2026, ($Million)
  • Table 10. Global Influenza Vaccine Market, By Route of Administration, 2018-2026, ($Million)
  • Table 11. Influenza Vaccine Market For Injection, By Region, 2018-2026, ($Million)
  • Table 12. Influenza Vaccine Market For Nasal Spray, By Region, 2018-2026, ($Million)
  • Table 13. Global Influenza Vaccine Market By Region, 2018-2026, ($Million)
  • Table 14. Canada Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 15. Canada Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 16. Canada Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 17. Canada Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 18. North America Influenza Vaccine Market By Country, 2018-2026, ($Million)
  • Table 19. U.S. Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 20. U.S. Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 21. U.S. Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 22. U.S. Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 23. Canada Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 24. Canada Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 25. Canada Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 26. Canada Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 27. Mexico Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 28. Mexico Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 29. Mexico Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 30. Mexico Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 31. Europe Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 32. Europe Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 33. Europe Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 34. Europe Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 35. Europe Influenza Vaccine Market By Country, 2018-2026, ($Million)
  • Table 36. Germany Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 37. Germany Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 38. Germany Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 39. Germany Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 40. France Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 41. France Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 42. France Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 43. France Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 44. Uk Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 45. Uk Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 46. Uk Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 47. Uk Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 48. Italy Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 49. Italy Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 50. Italy Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 51. Italy Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 52. Spain Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 53. Spain Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 54. Spain Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 55. Spain Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 56. Rest of Europe Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 57. Rest of Europe Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 58. Rest of Europe Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 59. Rest of Europe Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 60. Asia-Pacific Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 61. Asia-Pacific Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 62. Asia-Pacific Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 63. Asia-Pacific Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 64. Asia-Pacific Influenza Vaccine Market By Country, 2018-2026, ($Million)
  • Table 65. Japan Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 66. Japan Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 67. Japan Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 68. Japan Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 69. China Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 70. China Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 71. China Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 72. China Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 73. India Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 74. India Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 75. India Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 76. India Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 77. Australia Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 78. Australia Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 79. Australia Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 80. Australia Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 81. South Korea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 82. South Korea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 83. South Korea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 84. South Korea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 85. Rest of Asia-Pacific Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 86. Rest of Asia-Pacific Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 87. Rest of Asia-Pacific Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 88. Rest of Asia-Pacific Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 89. Lamea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 90. Lamea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 91. Lamea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 92. Lamea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 93. Lamea Influenza Vaccine Market By Country, 2018-2026, ($Million)
  • Table 94. Brazil Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 95. Brazil Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 96. Brazil Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 97. Brazil Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 98. Saudi Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 99. Saudi Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 100. Saudi Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 101. Saudi Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 102. South Africa Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 103. South Africa Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 104. South Africa Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 105. South Africa Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 106. Rest of Lamea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
  • Table 107. Rest of Lamea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
  • Table 108. Rest of Lamea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
  • Table 109. Rest of Lamea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
  • Table 110. Astrazeneca: Company Snapshot
  • Table 111. Astrazeneca: Operating Segments
  • Table 112. Astrazeneca: Product Portfolio
  • Table 113. Biodiem: Company Snapshot
  • Table 114. Biodiem: Operating Segments
  • Table 115. Biodiem: Product Portfolio
  • Table 116. Csl Limited: Company Snapshot
  • Table 117. Csl Limited: Operating Segments
  • Table 118. Csl Limited: Product Portfolio
  • Table 119. Emergent Biosolutions: Company Snapshot
  • Table 120. Emergent Biosolutions: Operating Segments
  • Table 121. Emergent Biosolutions: Product Portfolio
  • Table 122. Roche: Company Snapshot
  • Table 123. Roche: Operating Segments
  • Table 124. Roche: Product Portfolio
  • Table 125. Gamma Vaccines: Company Snapshot
  • Table 126. Gamma Vaccines: Operating Segments
  • Table 127. Gamma Vaccines: Product Type Portfolio
  • Table 128. Gsk: Company Snapshot
  • Table 129. Gsk: Operating Segments
  • Table 130. Gsk: Product Portfolio
  • Table 131. Merck.: Company Snapshot
  • Table 132. Merck: Operating Segments
  • Table 133. Merck: Product Type Portfolio
  • Table 134. Novartis: Company Snapshot
  • Table 135. Novartis: Operating Segments
  • Table 136. Novartis: Product Type Portfolio
  • Table 137. Pfizer: Company Snapshot
  • Table 138. Pfizer: Operating Segments
  • Table 139. Pfizer: Product Type Portfolio
  • Table 140. Sanofi: Company Snapshot
  • Table 141. Sanofi: Operating Segments
  • Table 142. Sanofi: Product Type Portfolio
  • Table 143. Sinovac Biotech: Company Snapshot
  • Table 144. Sinovac Biotech: Operating Segments
  • Table 145. Sinovac Biotech: Product Type Portfolio

List of Figures

  • Figure 01. Influenza Vaccine Market Segmentation
  • Figure 02. Top Investment Pockets
  • Figure 03. Top Winning Strategies, By Year, 2016-2019*
  • Figure 04. Top Winning Strategies, By Development, 2016-2019* (%)
  • Figure 05. Top Winning Strategies, By Company, 2016-2019*
  • Figure 06. Low-Moderate Bargaining Power of Suppliers
  • Figure 07. High Bargaining Power of Buyers
  • Figure 08. Moderate Threat of New Entrants
  • Figure 09. Moderate Threat of Substitution
  • Figure 10. High Intensity of Competitive Rivalry
  • Figure 11. Top Impacting Factors
  • Figure 12. Comparative Share Analysis of Influenza Vaccine For Quadrivalent, By Country, 2018 & 2026 (%)
  • Figure 13. Comparative Share Analysis of Influenza Vaccine Market For Trivalent, By Country, 2018 & 2026 (%)
  • Figure 14. Comparative Share Analysis of Egg-Based Influenza Vaccine, By Country, 2018 & 2026 (%)
  • Figure 15. Comparative Share Analysis of Cell Culture Influenza Vaccine Market, By Country, 2018 & 2026 (%)
  • Figure 16. Comparative Share Analysis of Influenza Vaccine For Pediatric Age Group, By Country, 2018 & 2026 (%)
  • Figure 17. Comparative Share Analysis of Influenza Vaccine Market For Adult Age Group, By Country, 2018 & 2026 (%)
  • Figure 18. Comparative Share Analysis of Influenza Vaccine For Injection, By Country, 2018 & 2026 (%)
  • Figure 19. Comparative Share Analysis of Influenza Vaccine Market For Nasal Spray, By Country, 2018 & 2026 (%)
  • Figure 20. Astrazeneca: Revenue, 2016-2018 ($Million)
  • Figure 21. Astrazeneca: Revenue Share By Segment, 2018 (%)
  • Figure 22. Astrazeneca: Revenue Share By Region, 2018 (%)
  • Figure 23. Biodiem: Revenue, 2016-2018 ($Million)
  • Figure 24. Csl Limited: Revenue, 2016-2018 ($Million)
  • Figure 25. Csl Limited: Revenue Share By Segment, 2018 (%)
  • Figure 26. Csl Limited: Revenue Share By Region, 2018 (%)
  • Figure 27. Emergent Biosolutions: Revenue, 2016-2018 ($Million)
  • Figure 28. Emergent Biosolutions: Revenue Share By Product, 2018 (%)
  • Figure 29. Emergent Biosolutions: Revenue Share By Region, 2018 (%)
  • Figure 30. Roche: Revenue, 2016-2018 ($Million)
  • Figure 31. Roche: Revenue Share By Segment, 2018 (%)
  • Figure 32. Roche: Revenue Share By Region, 2018 (%)
  • Figure 33. Gsk: Revenue, 2016-2018 ($Million)
  • Figure 34. Gsk: Revenue Share By Segment, 2018 (%)
  • Figure 35. Gsk: Revenue Share By Region, 2018 (%)
  • Figure 36. Merck: Revenue, 2016-2018 ($Million)
  • Figure 37. Merck: Revenue Share By Segment, 2018 (%)
  • Figure 38. Merck: Revenue Share By Region, 2018 (%)
  • Figure 39. Novartis: Revenue, 2016-2018 ($Million)
  • Figure 40. Novartis: Revenue Share By Segment, 2018 (%)
  • Figure 41. Novartis: Revenue Share By Region, 2018 (%)
  • Figure 42. Pfizer: Revenue, 2016-2018 ($Million)
  • Figure 43. Pfizer: Revenue Share By Segment, 2018 (%)
  • Figure 44. Pfizer: Revenue Share By Region, 2018 (%)
  • Figure 45. Sanofi: Revenue, 2016-2018 ($Million)
  • Figure 46. Sanofi: Revenue Share By Segment, 2018 (%)
  • Figure 47. Sanofi: Revenue Share By Region, 2018 (%)
  • Figure 48. Sinovac Biotech: Revenue, 2016-2018 ($Million)
  • Figure 49. Sinovac Biotech: Revenue Share By Product, 2018 (%)
  • Figure 50. Sinovac Biotech: Revenue Share By Region, 2018 (%)
目次
Product Code: LI_181437

Title:
Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2019-2026.

The global influenza vaccine market was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.

Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.

The key factors that drive the growth of the global influenza vaccine market include increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upsurge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.

The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global influenza vaccine market is provided.
  • An extensive analysis of various regions provides insights that allows companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Vaccine type

  • Quadrivalent
  • Trivalent

By Type

  • Seasonal
  • Pandemic

By Technology

  • Egg-based
  • Cell-based

By Age Group

  • Pediatric
  • Adult

By Route of Administration

  • Injection
  • Nasal Spray

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

KEY MARKET PLAYERS

  • AstraZeneca Plc.
  • Biodiem
  • CSL Limited
  • Emergent BioSolutions
  • F. Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi Pasteur SA
  • Sinovac Biotech Ltd.

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Benefits For Stakeholders
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Key Findings of The Study
  • 2.2. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter'S Five Force Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High Prevalence of Influenza
      • 3.4.1.2. Increase In Government Focus On Immunization Programs
      • 3.4.1.3. Emerging Vaccines
      • 3.4.1.4. Technological Progress In Vaccine Administration
    • 3.4.2. Restraints
      • 3.4.2.1. Longer Timelines And Implementation of Stringent Regulations
      • 3.4.2.2. High Costs Associated With The Development of Vaccines
    • 3.4.3. Opportunity
      • 3.4.3.1. High Growth Prospects In Emerging Markets

Chapter 4: Influenza Vaccine Market, By Vaccine Type

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Quadrivalent
    • 4.2.1. Key Market Trends And Opportunities
    • 4.2.2. Market Size And Forecast
    • 4.2.3. Market Analysis, By Country
  • 4.3. Trivalent
    • 4.3.1. Key Market Trends And Opportunities
    • 4.3.2. Market Size And Forecast
    • 4.3.3. Market Analysis, By Country

Chapter 5: Influenza Vaccine Market, By Type

  • 5.1. Overview
  • 5.2. Seasonal Influenza Vaccine
  • 5.3. Pandemic Influenza Vaccine

Chapter 6: Influenza Vaccine Market, By Technology

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast
  • 6.2. Egg-Based
    • 6.2.1. Market Size And Forecast
    • 6.2.2. Market Analysis, By Country
  • 6.3. Cell Culture
    • 6.3.1. Market Size And Forecast, By Region
    • 6.3.2. Market Analysis, By Country

Chapter 7: Influenza Vaccine Market, By Age Group

  • 7.1. Overview
    • 7.1.1. Market Size And Forecast
  • 7.2. Pediatric
    • 7.2.1. Market Size And Forecast, By Region
    • 7.2.2. Market Analysis, By Country
  • 7.3. Adult
    • 7.3.1. Market Size And Forecast, By Region
    • 7.3.2. Market Analysis, By Country

Chapter 8: Influenza Vaccine Market, By Route of Administration

  • 8.1. Overview
    • 8.1.1. Market Size And Forecast
  • 8.2. Injection
    • 8.2.1. Market Size And Forecast
    • 8.2.2. Market Analysis, By Country
  • 8.3. Nasal Spray
    • 8.3.1. Market Size And Forecast
    • 8.3.2. Market Analysis, By Country

Chapter 9: Global Influenza Vaccine Market, By Region

  • 9.1. Overview
    • 9.1.1. Market Size And Forecast
  • 9.2. North America
    • 9.2.1. Key Market Trends And Opportunities
    • 9.2.2. Market Size And Forecast, By Vaccine Type
    • 9.2.3. Market Size And Forecast, By Technology
    • 9.2.4. Market Size And Forecast, By Age Group
    • 9.2.5. Market Size And Forecast, By Route of Administration
    • 9.2.6. Market Size And Forecast, By Country
      • 9.2.6.1. U.S. Market Size And Forecast, By Vaccine Type
      • 9.2.6.2. U.S. Market Size And Forecast, By Technology
      • 9.2.6.3. U.S. Market Size And Forecast, By Age Group
      • 9.2.6.4. U.S. Market Size And Forecast, By Route of Administration
      • 9.2.6.5. Canada Market Size And Forecast, By Vaccine Type
      • 9.2.6.6. Canada Market Size And Forecast, By Technology
      • 9.2.6.7. Canada Market Size And Forecast, By Age Group
      • 9.2.6.8. Canada Market Size And Forecast, By Route of Administration
      • 9.2.6.9. Mexico Market Size And Forecast, By Vaccine Type
      • 9.2.6.10. Mexico Market Size And Forecast, By Technology
      • 9.2.6.11. Mexico Market Size And Forecast, By Age Group
      • 9.2.6.12. Mexico Market Size And Forecast, By Route of Administration
  • 9.3. Europe
    • 9.3.1. Key Market Trends And Opportunities
    • 9.3.2. Market Size And Forecast, By Vaccine Type
    • 9.3.3. Market Size And Forecast, By Technology
    • 9.3.4. Market Size And Forecast, By Age Group
    • 9.3.5. Market Size And Forecast, By Route of Administration
    • 9.3.6. Market Size And Forecast, By Country
      • 9.3.6.1. Germany Market Size And Forecast, By Vaccine Type
      • 9.3.6.2. Germany Market Size And Forecast, By Technology
      • 9.3.6.3. Germany Market Size And Forecast, By Age Group
      • 9.3.6.4. Germany Market Size And Forecast, By Route of Administration
      • 9.3.6.5. France Market Size And Forecast, By Vaccine Type
      • 9.3.6.6. France Market Size And Forecast, By Technology
      • 9.3.6.7. France Market Size And Forecast, By Age Group
      • 9.3.6.8. France Market Size And Forecast, By Route of Administration
      • 9.3.6.9. Uk Market Size And Forecast, By Vaccine Type
      • 9.3.6.10. Uk Market Size And Forecast, By Technology
      • 9.3.6.11. Uk Market Size And Forecast, By Age Group
      • 9.3.6.12. Uk Market Size And Forecast, By Route of Administration
      • 9.3.6.13. Italy Market Size And Forecast, By Vaccine Type
      • 9.3.6.14. Italy Market Size And Forecast, By Technology
      • 9.3.6.15. Italy Market Size And Forecast, By Age Group
      • 9.3.6.16. Italy Market Size And Forecast, By Route of Administration
      • 9.3.6.17. Spain Market Size And Forecast, By Vaccine Type
      • 9.3.6.18. Spain Market Size And Forecast, By Technology
      • 9.3.6.19. Spain Market Size And Forecast, By Age Group
      • 9.3.6.20. Spain Market Size And Forecast, By Route of Administration
      • 9.3.6.21. Rest of Europe Market Size And Forecast, By Vaccine Type
      • 9.3.6.22. Rest of Europe Market Size And Forecast, By Technology
      • 9.3.6.23. Rest of Europe Market Size And Forecast, By Age Group
      • 9.3.6.24. Rest of Europe Market Size And Forecast, By Route of Administration
  • 9.4. Asia-Pacific
    • 9.4.1. Key Market Trends And Opportunities
    • 9.4.2. Market Size And Forecast, By Vaccine Type
    • 9.4.3. Market Size And Forecast, By Technology
    • 9.4.4. Market Size And Forecast, By Age Group
    • 9.4.5. Market Size And Forecast, By Route of Administration
    • 9.4.6. Market Size And Forecast, By Country
      • 9.4.6.1. Japan Market Size And Forecast, By Vaccine Type
      • 9.4.6.2. Japan Market Size And Forecast, By Technology
      • 9.4.6.3. Japan Market Size And Forecast, By Age Group
      • 9.4.6.4. Japan Market Size And Forecast, By Route of Administration
      • 9.4.6.5. China Market Size And Forecast, By Vaccine Type
      • 9.4.6.6. China Market Size And Forecast, By Technology
      • 9.4.6.7. China Market Size And Forecast, By Age Group
      • 9.4.6.8. China Market Size And Forecast, By Route of Administration
      • 9.4.6.9. India Market Size And Forecast, By Vaccine Type
      • 9.4.6.10. India Market Size And Forecast, By Technology
      • 9.4.6.11. India Market Size And Forecast, By Age Group
      • 9.4.6.12. India Market Size And Forecast, By Route of Administration
      • 9.4.6.13. Australia Market Size And Forecast, By Vaccine Type
      • 9.4.6.14. Australia Market Size And Forecast, By Technology
      • 9.4.6.15. Australia Market Size And Forecast, By Age Group
      • 9.4.6.16. Australia Market Size And Forecast, By Route of Administration
      • 9.4.6.17. South Korea Market Size And Forecast, By Vaccine Type
      • 9.4.6.18. South Korea Market Size And Forecast, By Technology
      • 9.4.6.19. South Korea Market Size And Forecast, By Age Group
      • 9.4.6.20. South Korea Market Size And Forecast, By Route of Administration
      • 9.4.6.21. Rest of Asia-Pacific Market Size And Forecast, By Vaccine Type
      • 9.4.6.22. Rest of Asia-Pacific Market Size And Forecast, By Technology
      • 9.4.6.23. Rest of Asia-Pacific Market Size And Forecast, By Age Group
      • 9.4.6.24. Rest of Asia-Pacific Market Size And Forecast, By Route of Administration
  • 9.5. Lamea
    • 9.5.1. Key Market Trends And Opportunities
    • 9.5.2. Market Size And Forecast, By Vaccine Type
    • 9.5.3. Market Size And Forecast, By Technology
    • 9.5.4. Market Size And Forecast, By Age Group
    • 9.5.5. Market Size And Forecast, By Route of Administration
    • 9.5.6. Market Size And Forecast, By Country
      • 9.5.6.1. Brazil Market Size And Forecast, By Vaccine Type
      • 9.5.6.2. Brazil Market Size And Forecast, By Technology
      • 9.5.6.3. Brazil Market Size And Forecast, By Age Group
      • 9.5.6.4. Brazil Market Size And Forecast, By Route of Administration
      • 9.5.6.5. Saudi Market Size And Forecast, By Vaccine Type
      • 9.5.6.6. Saudi Market Size And Forecast, By Technology
      • 9.5.6.7. Saudi Market Size And Forecast, By Age Group
      • 9.5.6.8. Saudi Market Size And Forecast, By Route of Administration
      • 9.5.6.9. South Africa Market Size And Forecast, By Vaccine Type
      • 9.5.6.10. South Africa Market Size And Forecast, By Technology
      • 9.5.6.11. South Africa Market Size And Forecast, By Age Group
      • 9.5.6.12. South Africa Market Size And Forecast, By Route of Administration
      • 9.5.6.13. Rest of Lamea Market Size And Forecast, By Vaccine Type
      • 9.5.6.14. Rest of Lamea Market Size And Forecast, By Technology
      • 9.5.6.15. Rest of Lamea Market Size And Forecast, By Age Group
      • 9.5.6.16. Rest of Lamea Market Size And Forecast, By Route of Administration

Chapter 10: Company Profiles

  • 10.1. Astrazeneca Plc (Astrazeneca)
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Operating Business Segments
    • 10.1.4. Product Portfolio
    • 10.1.5. Business Performance
  • 10.2. Biodiem
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Operating Business Segments
    • 10.2.4. Product Portfolio
    • 10.2.5. Business Performance
  • 10.3. Csl Limited (Seqirus Gmbh)
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Operating Business Segments
    • 10.3.4. Product Portfolio
    • 10.3.5. Business Performance
    • 10.3.6. Key Strategic Moves And Developments
  • 10.4. Emergent Biosolutions
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Operating Business Segments
    • 10.4.4. Product Portfolio
    • 10.4.5. Business Performance
  • 10.5. F. Hoffmann-La Roche Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Operating Business Segments
    • 10.5.4. Product Portfolio
    • 10.5.5. Business Performance
  • 10.6. Gamma Vaccines Pty Ltd.
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Operating Business Segments
    • 10.6.4. Product Portfolio
  • 10.7. Glaxosmithkline Plc
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Operating Business Segments
    • 10.7.4. Product Portfolio
    • 10.7.5. Business Performance
    • 10.7.6. Key Strategic Moves And Developments
  • 10.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Operating Business Segments
    • 10.8.4. Product Portfolio
    • 10.8.5. Business Performance
  • 10.9. Novartis Ag
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Operating Business Segments
    • 10.9.4. Product Portfolio
    • 10.9.5. Business Performance
  • 10.10. Pfizer, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Operating Business Segments
    • 10.10.4. Product Portfolio
    • 10.10.5. Business Performance
    • 10.10.6. Key Strategic Moves And Developments
  • 10.11. Sanofi
    • 10.11.1. Company Overview
    • 10.11.2. Company Snapshot
    • 10.11.3. Operating Business Segments
    • 10.11.4. Product Portfolio
    • 10.11.5. Business Performance
  • 10.12. Sinovac Biotech Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Company Snapshot
    • 10.12.3. Operating Business Segments
    • 10.12.4. Product Portfolio
    • 10.12.5. Business Performance